These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 16643616

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [Abstract] [Full Text] [Related]

  • 3. Free and total human glandular kallikrein 2 in patients with prostate cancer.
    Väisänen V, Pettersson K, Alanen K, Viitanen T, Nurmi M.
    Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
    [Abstract] [Full Text] [Related]

  • 4. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
    Stephan C, Meyer HA, Paul EM, Kristiansen G, Loening SA, Lein M, Jung K.
    Anticancer Res; 2007 Jul; 27(4A):1833-6. PubMed ID: 17649780
    [Abstract] [Full Text] [Related]

  • 5. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
    Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M, Scardino PT, Huland E, Huland H, Lilja H.
    Prostate; 2003 Feb 15; 54(3):181-6. PubMed ID: 12518322
    [Abstract] [Full Text] [Related]

  • 10. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM.
    Cancer Res; 2002 Oct 15; 62(20):5974-9. PubMed ID: 12384565
    [Abstract] [Full Text] [Related]

  • 11. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lümmen G, Tscholl R.
    Urology; 2000 Apr 15; 55(4):481-5. PubMed ID: 10736487
    [Abstract] [Full Text] [Related]

  • 12. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
    Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP.
    BJU Int; 2005 Sep 15; 96(4):521-7. PubMed ID: 16104903
    [Abstract] [Full Text] [Related]

  • 13. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.
    Eur Urol; 2009 Mar 15; 55(3):563-74. PubMed ID: 19058905
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FK, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H.
    Int J Cancer; 2006 Mar 01; 118(5):1234-40. PubMed ID: 16152616
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, Pagano F, Diamandis EP.
    Prostate; 2003 Feb 15; 54(3):220-9. PubMed ID: 12518327
    [Abstract] [Full Text] [Related]

  • 18. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T, Schalken J, Wittjes W, Ljungberg B, Lilja H.
    Prostate; 2001 Apr 15; 47(1):14-20. PubMed ID: 11304725
    [Abstract] [Full Text] [Related]

  • 19. [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score].
    Song G, Zhou LQ, He ZS, Li NC, Li M, Hao JR, Pan BN, Na YQ.
    Zhonghua Wai Ke Za Zhi; 2006 Mar 15; 44(6):376-8. PubMed ID: 16638345
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.